Paolo Tarantino, Research Fellow Dana-Farber Cancer Institute and Harvard Medical Schoolpost, shared a post on X:
“The new Enhertu?
Presented at ASCO26, the FIH phase 1/2 trial of SYS6043 (n=627) shows impressive activity across a wide variety of tumor types. Mostly hematologic and GI tox, though ILD was observed, despite Fc engineering. No relationship of efficacy with B7H3 expression.”
Other articles featuring Paolo Tarantino on OncoDaily.
